WEST LAFAYETTE, Ind. – Vancomycin-resistant enterococcus (VRE) is among the leading causes of hospital-acquired infections in the United States. An estimated 20,000 people in the U.S. become infected with it each year, and nearly 10% of people who get it die from it.
These superbugs typically develop from infections in the intestinal tract, where the bacteria become resistant to the antibiotic vancomycin. People who stay in a hospital have the highest odds of getting VRE.
A pair of Purdue University researchers from the College of Pharmacy and the College of Veterinary Medicine developed small molecules to combat deadly, drug-resistant enterococcus.
They created their molecules by repurposing a drug that has been used for more than 80 years to treat glaucoma, congestive heart failure and some other health issues. Their work is published in the Journal of Medicinal Chemistry.
“The potency of these molecules and the ability to tune the molecules’ properties to target VRE in different compartments of the body make this an exciting project,” said Daniel Flaherty, an assistant professor of medicinal chemistry and molecular pharmacology. “I believe our discovery may help to change the way people treat VRE in the future.
“We can have molecules that can be used to treat deadly systemic VRE infections, or through manipulation of the properties of the molecule, design a compound that will reside solely in the gastrointestinal tract to reduce VRE colonization. By working across disciplines at Purdue, we have been able to improve the effectiveness of this drug 600 times better than where we started in treating VRE.”
Mohamed Seleem, a professor of microbiology, who co-created the molecules with Flaherty, said the problem with antibiotics on the market is that they are used for a wide variety of illnesses.
“These antibiotics can really rip apart the guts and destroy good bacteria,” Seleem said. “Then someone can develop Clostridium difficile, also known as C. diff, which kills about 30,000 people each year in the United States. Scientists across the globe are working on better solutions, but I think we are far away from seeing narrow-spectrum antibiotics proliferate the market.”
The Purdue team’s small molecules have been shown to target VRE and have the properties necessary to treat VRE in both systemic circulation or in the GI tract, where all VRE infections originate.
###
The scientists have worked with the Purdue Research Foundation Office of Technology Commercialization on patenting the technology.
The innovators and OTC are looking for partners to continue developing their technology. For more information on licensing and other opportunities, contact Abhijit Karve of OTC at [email protected].
About Purdue Research Foundation Office of Technology Commercialization
The Purdue Research Foundation Office of Technology Commercialization operates one of the most comprehensive technology transfer programs among leading research universities in the U.S. Services provided by this office support the economic development initiatives of Purdue University and benefit the university’s academic activities through commercializing, licensing and protecting Purdue intellectual property. The office recently moved into the Convergence Center for Innovation and Collaboration in Discovery Park District, adjacent to the Purdue campus. In fiscal year 2020, the office reported 148 deals finalized with 225 technologies signed, 408 disclosures received and 180 issued U.S. patents. The office is managed by the Purdue Research Foundation, which received the 2019 Innovation and Economic Prosperity Universities Award for Place from the Association of Public and Land-grant Universities. In 2020, IPWatchdog Institute ranked Purdue third nationally in startup creation and in the top 20 for patents. The Purdue Research Foundation is a private, nonprofit foundation created to advance the mission of Purdue University. Contact [email protected] for more information.
About Purdue University
Purdue University is a top public research institution developing practical solutions to today’s toughest challenges. Ranked the No. 6 Most Innovative University in the United States by U.S. News & World Report, Purdue delivers world-changing research and out-of-this-world discovery. Committed to hands-on and online, real-world learning, Purdue offers a transformative education to all. Committed to affordability and accessibility, Purdue has frozen tuition and most fees at 2012-13 levels, enabling more students than ever to graduate debt-free. See how Purdue never stops in the persistent pursuit of the next giant leap at purdue.edu.
Writer: Chris Adam, 765-588-3341, [email protected]
Sources: Daniel Flaherty, [email protected]
Mohamed Seleem, [email protected]
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.
